Integrated Filing — IndAS



General information about company

Scrip Code 524558
NSE Symbol NEULANDLAB
MSEI Symbol NOTLISTED
ISIN INE794A01010
Name of company Neuland Laboratories Limited
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2025
Date of end of financial year 31-03-2026
Date of board meeting when results were approved 07-11-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 24-10-2025
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Consolidated
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Manufacturing of Active Pharmaceuticals
Start date and time of board meeting 07-11-2025   14:35:00
End date and time of board meeting 07-11-2025   16:05:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
1 Income
Revenue from operations 51,427.31 80,702.58
Other income 179.97 965.56
Total income 51,607.28 81,668.14
2 Expenses
(a) Cost of materials consumed 22,764.00 38,912.04
(b) Purchases of stock-in-trade 0.00 0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (4,403.10) (9,196.75)
(d) Employee benefit expense 8,037.23 15,383.74
(e) Finance costs 536.71 995.20
(f) Depreciation, depletion and amortisation expense 2,254.15 4,273.10
(f) Other Expenses
1 Manufacturing Expenses 4,595.62 8,533.10
2 Other Expenses 4,879.02 8,067.02
Total other expenses 9,474.64 16,600.12
Total expenses 38,663.63 66,967.45
3 Total profit before exceptional items and tax 12,943.65 14,700.69
4 Exceptional items 0.00 0.00
5 Total profit before tax 12,943.65 14,700.69
6 Tax expense
7 Current tax 3,251.25 3,687.93
8 Deferred tax 7.01 (62.63)
9 Total tax expenses 3,258.26 3,625.30
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 9,685.39 11,075.39
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 9,685.39 11,075.39
17 Other comprehensive income net of taxes (10.83) (0.91)
18 Total Comprehensive Income for the period 9,674.56 11,074.48
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent 0.00 0.00
Total profit or loss, attributable to non-controlling interests 0.00 0.00
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent 0.00 0.00
Total comprehensive income for the period attributable to owners of parent non-controlling interests 0.00 0.00
21 Details of equity share capital
Paid-up equity share capital 1,290.05 1,290.05
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 75.49 86.32
Diluted earnings (loss) per share from continuing operations 75.49 86.32
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 75.49 86.32
Diluted earnings (loss) per share from continuing and discontinued operations 75.49 86.32
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results

Textual Information(1) 1. The financial results for the quarter and half year ended September 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on November 07, 2025. The Statutory auditor have issued an unmodified opinion in respect of the limited review for the quarter and half year ended September 30, 2025. 2. The financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. 3. The consolidated financial results include results of the following wholly owned subsidiaries: (a) Neuland Laboratories Inc., USA (b) Neuland Laboratories KK., Japan. 4. The operations of the Company are predominantly related to the manufacture and sale of active pharmaceutical ingredients and allied services. As such there is only one primary reportable segment as per Ind AS 108 Operating Segments. 5. During the previous year, the Company has fully transferred an investment property located in Nanakramguda, Hyderabad, Telangana, through perpetual lease, resulting in total profit of Rs. 7,640.36 lakhs (For the Half year ended September 30, 2024: Rs. 2,062.56 lakhs) being the profit is exceptional in nature, it has been disclosed as a separate line item. 6. The EPS for quarters has not been annualised.



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2025
Date of end of reporting period 30-09-2025
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Consolidated
Assets
1 Non-current assets
Property, plant and equipment 78,758.79
Capital work-in-progress 13,995.35
Investment property 0.00
Goodwill 27,946.10
Other intangible assets 591.64
Intangible assets under development 294.27
Biological assets other than bearer plants 0.00
Investments accounted for using equity method 0.00
Non-current financial assets
Non-current investments 152.89
Trade receivables, non-current 0.00
Loans, non-current 0.00
Other non-current financial assets 1,147.29
Total non-current financial assets 1,300.18
Deferred tax assets (net) 0.00
Other non-current assets 3,960.42
Total non-current assets 1,26,846.75
2 Current assets
Inventories 54,789.82
Current financial asset
Current investments 11,215.24
Trade receivables, current 44,092.14
Cash and cash equivalents 4,134.18
Bank balance other than cash and cash equivalents 1,522.10
Loans, current 0.00
Other current financial assets 1,094.22
Total current financial assets 62,057.88
Current tax assets (net) 0.00
Other current assets 9,708.94
Total current assets 1,26,556.64
3 Non-current assets classified as held for sale 0.00
4 Regulatory deferral account debit balances and related deferred tax Assets 0.00
Total assets 2,53,403.39
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 1,290.05
Other equity 1,60,725.46
Total equity attributable to owners of parent 1,62,015.51
Non controlling interest 0.00
Total equity 1,62,015.51
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 8,922.43
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0.00
Total Trade payable 0.00
Other non-current financial liabilities 10,110.57
Total non-current financial liabilities 19,033.00
Provisions, non-current 716.92
Deferred tax liabilities (net) 7,209.76
Deferred government grants, Non-current 0.00
Other non-current liabilities 0.00
Total non-current liabilities 26,959.68
Current liabilities
Current financial liabilities
Borrowings, current 7,096.29
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 1,354.42
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 27,627.95
Total Trade payable 28,982.37
Other current financial liabilities 8,852.56
Total current financial liabilities 44,931.22
Other current liabilities 19,247.14
Provisions, current 244.77
Current tax liabilities (Net) 5.07
Deferred government grants, Current 0.00
Total current liabilities 64,428.20
3 Liabilities directly associated with assets in disposal group classified as held for sale 0.00
4 Regulatory deferral account credit balances and related deferred tax liability 0.00
Total liabilities 91,387.88
Total equity and liabilites 2,53,403.39
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2025 01-04-2025
Date of end of reporting period 30-09-2025 30-09-2025
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Consolidated Consolidated
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2025 01-04-2025
B Date of end of reporting period 30-09-2025 30-09-2025
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Consolidated Consolidated
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gain/(loss) on defined benefit plans (39.11) (39.11)
2 Equity instruments through other comprehensive income 0.00 0.00
Total Amount of items that will not be reclassified to profit and loss (39.11) (39.11)
2 Income tax relating to items that will not be reclassified to profit or loss (9.84) (9.84)
3 Amount of items that will be reclassified to profit and loss
1 Exchange differences in translating the financial statements of foreign operations 18.44 28.36
Total Amount of items that will be reclassified to profit and loss 18.44 28.36
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income (10.83) (0.91)



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2025
B Date of end of reporting period 30-09-2025
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Consolidated
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 14,700.69
Adjustments for reconcile profit (loss)
Adjustments for finance costs 995.20
Adjustments for decrease (increase) in inventories (16,214.13)
Adjustments for decrease (increase) in trade receivables, current (12,318.90)
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets (2,763.80)
Adjustments for decrease (increase) in other non-current assets 0.00
Adjustments for other financial assets, non-current (211.19)
Adjustments for other financial assets, current (1,458.15)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current 3,404.68
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 10,944.53
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 4,273.10
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current 35.05
Adjustments for provisions, non-current (44.42)
Adjustments for other financial liabilities, current (897.70)
Adjustments for other financial liabilities, non-current 0.00
Adjustments for unrealised foreign exchange losses gains 697.53
Adjustments for dividend income 0.00
Adjustments for interest income 518.59
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) (446.97)
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 0.00
Other adjustments for non-cash items 140.65
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (14,383.11)
Net cash flows from (used in) operations 317.58
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 3,992.26
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities (3,674.68)
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 0.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 43.84
Purchase of property, plant and equipment 16,541.59
Proceeds from sales of investment property 0.00
Purchase of investment property 0.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 533.01
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 0.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 0.00
Interest received 641.88
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 11,169.38
Net cash flows from (used in) investing activities (5,219.50)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 4,774.03
Repayments of borrowings 2,345.16
Payments of lease liabilities 84.43
Dividends paid 1,539.59
Interest paid 997.89
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities (193.04)
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes (9,087.22)
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 28.36
Net increase (decrease) in cash and cash equivalents (9,058.86)
Cash and cash equivalents cash flow statement at beginning of period 13,193.04
Cash and cash equivalents cash flow statement at end of period 4,134.18